drugset
drugset / Trial / NCT03444714

Phase I Study of RiMO-301 With Radiation in Advanced Tumors

NCT03444714 ↗

Phase 1 Completed 32 enrolled Coordination Pharmaceuticals, Inc. University of Chicago · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with radiation in patients with advanced tumors. A single escalation dose of RiMO-301 is intratumorally injected in a 3 + 3 study design to identify the recommended dose and dosing volumes. Condition or Disease: Patient with advanced tumor which is clinically accessible for intratumoral injection Intervention/Treatment: Drug - RiMO-301 Radiation - Radiotherapy Phase: Phase 1

Timeline

Start
2018-04-10
Primary completion
2025-06-16
Completion
2025-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject RiMO-301 Unknown 5 % Other
Subject RiMO-301 Unknown 10 % Other
Subject RiMO-301 Unknown 15 % Other

Indications

No indication recorded.